BioNTech

生物科技巨头逆势加仓，BioNTech迎来机构抄底潮

Brett Shapiro - March 19, 2026

从mRNA到抗体疗法：BioNTech战略转型背后的机遇与挑战

angelina - March 18, 2026

Leadership Transition at BioNTech: A Strategic Pivot Underway

angelina - March 18, 2026

BioNTech战略转向：押注抗体疗法的千亿豪赌

kashif hafeez - March 17, 2026

创始人双双离职引发震荡，BioNTech股价遭遇重挫

March 15, 2026

Leadership Transition and Revenue Pressures Weigh on BioNTech Shares

kashif hafeez - March 14, 2026

BioNTech面临双重考验：创始人离任与营收下滑

kashif hafeez - March 14, 2026

创始人卸任与业绩预警双重打击，BioNTech股价遭遇重挫

angelina - March 13, 2026

BioNTech股价遭遇双重打击：创始人离职与营收预警引发市场震荡

Brett Shapiro - March 12, 2026

Leadership Transition and Financial Headwinds Weigh on BioNTech Shares

angelina - March 11, 2026

百欧恩泰转型之路：千亿现金储备押注肿瘤治疗新纪元

Brett Shapiro - March 9, 2026

BioNTech Shares Face Critical Test Amid Strategic Pivot

angelina - March 8, 2026

BioNTech Shares Face Technical Test Ahead of Earnings

Brett Shapiro - March 7, 2026

BioNTech财报前瞻：关键动向与市场博弈

kashif hafeez - March 7, 2026

BioNTech面临巨额法律风险，投资者聚焦财报日

Brett Shapiro - March 5, 2026

12 3...6 Page 1 of 6